Potassium metabolism in extremely low birth weight infants in the first week of life

J M Lorenz1, L I Kleinman, K Markarian

  • 1Department of Pediatrics and Human Development, Michigan State University, East Lansing, USA.

Insights

Extremely low birth weight infants often experience hyperkalemia due to potassium shifts. This study found that increased kidney function during diuresis helps normalize potassium levels, with initial shifts being key to hyperkalemia development.

Area of Science:

  • Neonatal physiology
  • Pediatric nephrology
  • Intensive care medicine

Background:

  • Nonoliguric hyperkalemia affects up to 50% of extremely low birth weight (ELBW) infants in the first week of life.
  • Understanding potassium metabolism is crucial for managing fluid and electrolyte balance in these vulnerable infants.

Purpose of the Study:

  • To characterize potassium metabolism and renal function in ELBW infants during the first five days of life.
  • To identify factors contributing to the development of nonoliguric hyperkalemia in ELBW infants.

Main Methods:

  • Studied plasma potassium concentration (PK), potassium intake/output, and renal clearances in 31 ELBW infants (birth weight ≤ 1000 gm) for six days.
  • Defined prediuresis, diuresis, and postdiuresis phases based on urine flow rate and weight loss.
  • Identified hyperkalemia as PK > 6.7 mmol/L.

Main Results:

  • PK initially increased post-birth, then decreased and stabilized by day four, irrespective of potassium intake.
  • Diuresis occurred in 27/31 infants, coinciding with a decrease in PK due to negative potassium balance.
  • Hyperkalemia (11/31 infants) was associated with a greater initial post-birth rise in PK, not differences in renal function or fluid homeostasis.

Conclusions:

  • Elevated PK in ELBW infants is primarily due to intracellular-to-extracellular potassium shifts post-birth.
  • Onset of diuresis enhances potassium excretion via increased GFR and sodium excretion, leading to PK normalization.
  • Hyperkalemia in ELBW infants likely results from an exaggerated initial intracellular-to-extracellular potassium shift.
Abstract

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...